Hair Loss Was Just the Start. Ozempic Users Are Also Reporting Nail Trouble
GLP-1 medications like semaglutide and tirzepatide may come with some unexpected hair-raising side effects, research out this week suggests—or rather, hair- and nail-losing ones. Scientists in Europe studied hundreds of people taking a GLP-1. Compared to non-users, people on GLP-1s were significantly more likely to develop hair loss and nail-related problems, particularly nail detachment, they found.
- ▪GLP-1 medications like semaglutide and tirzepatide may come with some unexpected hair-raising side effects, research out this week suggests—or rather, hair- and nail-losing ones.
- ▪Scientists in Europe studied hundreds of people taking a GLP-1.
- ▪Compared to non-users, people on GLP-1s were significantly more likely to develop hair loss and nail-related problems, particularly nail detachment, they found.
Gizmodo files mainly under tech. We currently carry 1,573 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Gizmodo |
| Canonical URL | https://gizmodo.com/hair-loss-was-just-the-start-ozempic-users-are-also-reporting-nail-trouble-2000820821 |
| Publication time | Fri, 02 Oct 2026 19:25:43 +0000 |
| Retrieval time | 2026-10-02T19:31:15.906Z |
| Last seen | 2026-10-02T19:31:15.906Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | -IlH_kEXLtKH · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
GLP-1 medications like semaglutide and tirzepatide may come with some unexpected hair-raising side effects, research out this week suggests—or rather, hair- and nail-losing ones. Scientists in Europe studied hundreds of people taking a GLP-1. Compared to non-users, people on GLP-1s were significantly more likely to develop hair loss and nail-related problems, particularly nail detachment, they found. Though these issues aren’t necessarily too serious, both patients and doctors should be aware of the potential risk, the researchers…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Gizmodo.
Discussion
0 commentsMore from Gizmodo
